Altered action of angiotensin II in patients with type 2 diabetes mellitus of recent onset

What Was Tested

This randomized controlled trial paper looks at Angiotensin II.

In the past it had been documented that some biological actions of Ang II are altered in diabetes.

The researchers addressed the issue of whether this is also true for its action on insulin sensitivity.

Who Took Part

The study group was 15 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

What Was Measured

The subject headings attached to it are Angiotensin II, Diabetes Mellitus, Type 2, Glucose Clamp Technique, Insulin, Muscle, Skeletal, Regional Blood Flow and Renal Circulation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 15 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1997 (Journal of hypertension), a journal based in Netherlands.

More context: the Angiotensin II compound page, all human trials.